Journal of Clinical Oncology
Articles in this Issue
Identification of patients at high risk for relapse by Merlin assay (CP-GEP) in an independent cohort of melanoma patients (pts) that did not undergo sentinel lymph node biopsy: An H&N subgroup analysis.
9567 Background: Sentinel lymph node biopsy (SLNB) is still the gold standard for nodal assessment used in the clinical staging of cutaneous melanoma (CM)...
On-shift resident education about hematologic and oncologic emergencies: A needs-based assessment.
9020 Background: Hematology/oncology (H/O) is a fundamental topic for the American Board of Internal Medicine (ABIM); however, there are few resources des...
The impact of cannabis use on patient outcomes post immune checkpoint inhibitor (ICI) therapy in a longitudinal observational trial: The DiRECT Cohort.
12081 Background: Prior small retrospective studies suggest that cannabis might compromise the efficacy of ICIs for cancer therapy due to its immunosuppre...
First-in-class PD-1/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC).
8509 Background: IBI363 is a first-in-class PD-1/IL-2 α-bias bispecific antibody f...
ctDNA tumor fraction (TF) to predict response to nivolumab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): An analysis of the multicentric phase 2 TOPNIVO trial.
6047 Background: Anti-PD1 provides clinical benefits in HNSCC, yet biomarkers of response remain poorly defined. In other cancer types, measures of ctDNA...
Efficacy and toxicity of low-doses versus standard-dose enzalutamide in advanced prostate cancer: A real-world study with implications for cancer prevention/interception.
10527 Background: Prostate cancer (PCa) is the most frequent cancer in males in the US and EU. Enzalutamide is effective in biochemically recurrent and ad...
Cell-free DNA 5-hydroxymethylcytosine profiling for the assessment of colorectal cancer biology and treatment response in blood.
3585 Background: Colorectal cancer is the third most common cancer worldwide, accounting for about 10% of all cancer cases, and is expected to claim more...
Breast cancer in the Rio Grande Valley: Telemedicine as a solution in the disruption in breast cancer care during COVID-19 pandemic.
e13578 Background: The COVID-19 pandemic significantly disrupted cancer care globally, posing challenges to the timely diagnosis and treatment of patients...
ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG).
3503 Background: Despite adjuvant chemotherapy (ACT) a proportion of patients (pts) with stage III colon cancer (CC) will...
Next generation sequencing (NGS) of malignant effusions and comparison to blood liquid biopsy (ctDNA): A community experience.
e20661 Background: NGS of cancer cells is critical in guiding personalized cancer treatment. While tissue-based NGS is the gold standard, obtaining suffic...
Brain metastasis: Incidence, trend analysis, and impact on survival using SEER database (2010-2020).
2021 Background: Brain metastasis has a poor prognosis in cancer patients with high morbidity and mortality rates. An updated comprehensive analysis of pa...
Real-world (rw) patient characteristics, treatment (tx) patterns, and clinical outcomes in advanced (adv) and recurrent (rec) endometrial cancer (EC) patients (pts) with known mismatch repair/microsatellite instability (MMR/MSI) status in Canada.
e23308 Background: Molecular characterization and treatments for adv/rec EC have evolved in recent years. Given limited biomarker-based data on EC reporte...
Comprehensive tumor mutational burden assessment using target-enhanced whole genome sequencing: A comparison with targeted panel testing.
e15090 Background: Tumor Mutational Burden (TMB) is a critical biomarker for predicting immunotherapy response in oncology. However, targeted panels, limi...
A phase II study of niraparib (N), abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa; HARMONY).
TPS5130 Background: Patients with prostate cancer and deleterious HRRa have poorer prognosis but derive benefit from poly (ADP-ribose) polymerase (PARP) i...
Effects of a deep learning network on imaging quality of low- <i>b</i> -value diffusion–weighted imaging and lesion detection in prostate cancer.
e17163 Background: Diffusion–weighted imaging with higher b -value improves detection rate for prostate cancer lesions. However, o...
A phase 1a/1b trial in relapsed/refractory T-cell non-Hodgkin lymphoma to determine the safety profile, pharmacology, and maximum tolerated dose of ST-001, an intravenous fenretinide phospholipid suspension (12.5 mg/mL).
TPS7096 Background: N-(4-hydroxyphenyl)retinamide (4-HPR; fenretinide) is a synthetic amide derivative of all-trans retinoic acid. Clinical data from tria...
Chitinase 3-like-1 <i>(CHI3L1):</i> A potential prognostic biomarker for immunotherapy (IO) in non-small cell lung cancer (NSCLC).
e20622 Background: CHI3L1 is a member of the 18-glycosyl hydrolase gene family and is produced by a variety of cells including tumors and immu...
ETER901: A randomized, open-label, phase III trial of anlotinib in combination with anti-PD-L1 antibody benmelstobart (TQB2450) versus nab-paclitaxel in first-line treatment of recurrent or metastatic triple-negative breast cancer.
1104 Background: Recurrent or metastatic triple-negative breast cancer (TNBC) represents an aggressive malignancy with unfavorable prognoses. Benmelstobar...
Long-term outcomes of toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: Results from a phase II trial.
e16028 Background: This study presents the long-term overall survival outcomes from a phase II clinical trial investigating the efficacy of toripalimab in...
E7386 study 102: Global dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced endometrial cancer (aEC) that progressed on platinum-based chemotherapy (chemo) and an anti-PD-(L)1 immunotherapy (IO).
5599 Background: There is a need for novel therapies for aEC that recurs after chemo and IO. LEN has antitumor activity in pts with aEC after platinum-bas...
Real-world patient characteristics and treatment patterns among cholangiocarcinoma patients treated with FGFR inhibitors.
e16262 Background: Pemigatinib and futibatinib are targeted therapies approved by the US Food and Drug Administration in 2020 and 2022, respectively, for...
Chemokines as predictive biomarkers for immune checkpoint inhibitor (ICI) efficacy in triple negative breast cancer (TNBC).
1106 Background: TNBC, although an aggressive breast cancer (BC) subtype, is highly immunogenic and the only BC subtype where the ICI pembrolizumab is app...
Investigating the oncolytic bacteria product SGN1 and its impact on PD-L1 expression, CD8+ T cell infiltration, and synergy with anti-PD-L1 combo in preclinical models of pancreatic adenocarcinoma, hepatocellular cancer, and melanoma.
e15188 Background: Despite success of immunotherapy in a wide range of solid tumors, immune checkpoint inhibitors (ICIs, such as α-PD-1 or α-PD-L1) remain...
Use of recombinant Newcastle disease virus expressing TRAIL to overcome resistance and enhance apoptosis in colorectal cancer models.
e15526 Background: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent, but its efficacy is limited in TRAIL-r...
The gut microbiome in pediatric diffuse midline gliomas: Correlative study results from the PNOC022 trial.
10015 Background: The gut microbiome exerts a multifaceted influence on treatment outcomes across various cancers, yet its potential role in diffuse midli...